Polivy 30 mg
Polivy (polatuzumab vedotin-piiq) is a medication indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, in combination with bendamustine and rituximab, following at least two prior therapies, unless otherwise specified.
Each vial of Polivy 30 mg Infusion Concentrate Powder contains 30 mg of polatuzumab vedotin. After reconstitution, each milliliter contains 20 mg of polatuzumab vedotin.
Polivy 30 mg You can contact us to find out the price:
Contact for detailed information